Plasmid DNA Vaccine Development Guidance Under Revision At FDA
This article was originally published in The Pink Sheet Daily
The Center for Biologics Evaluation & Research is proposing to no longer require preclinical autoimmune studies. Other proposed revisions to the 1996 guidance include accelerating the dosing schedule and using the highest dose planned for clinical administration in toxicity studies.
You may also be interested in...
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.
Companies will share data from the proof-of-concept study, but they do not intend to commercially pursue the use of both drugs in combination.